Latest Conference Coverage

Syn-One Test Reports High Sensitivity and Specificity Across Multiple Synucleinopathies

CND Life Sciences’ α-synuclein skin biopsy test showed sensitivity rates ranging from 92.7% to 100% across a number of assessed and clinically confirmed synucleinopathies, including Parkinson disease and dementia with Lewy bodies, among others.

Common Migraine Prodromal Symptoms Improved Through Acute Ubrogepant

A greater proportion of patients on ubrogepant reported absence of moderate-to-severe intensity headache within 48 hours, ability to function normally, and absence of headache of any intensity.

Early Progress From the World Brain Study: Imad Najm, MD

The director of Cleveland Clinic’s Epilepsy Center provided an update on the World Brain Study, a large-scale, longitudinal study aimed to observe the early, underlying changes in neurological disorders. [WATCH TIME: 9 minutes]

NeuroVoices: John Greenfield, MD, PhD, on the Growth of Neurology and the Budding Young Community of Neurologists

The president elect of the Association of University Professors of Neurology provided thoughts on the promising concepts in neurology and the reasons young medical professionals should join the field.

ALS Agent SAR443820 Shows High CNS Penetration, Promising Safety Profile in Phase 1 Study

In single-ascending dose and multiple-ascending dose studies, no clinically meaningful changes were noted in hematology, chemistry, vital signs, or electrocardiogram parameters.

Cell Therapy NRTX-1001 Posts Positive Preliminary Data in Drug-Resistant Mesial Temporal Lobe Epilepsy

Neurona Therapeutics’ single-administration allogeneic cell therapy suggests thus far that the treatment is safe, with signs of efficacy, after reading out data from the first 2 patients dosed.

Improving Diagnosis, Screening Patients More Efficiently in Alzheimer Disease: Katherine Turk, MD

The behavioral neurologist at VA Boston Healthcare System talked about screening patients for mild cognitive impairment to improve diagnosis in Alzheimer disease at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

Disease Activity in Early-Stage Relapsing MS Remains Minimal After 4 Years of Ocrelizumab Treatment

After 192 weeks, more than 90% of patients on ocrelizumab had no relapses and slightly more than 80% had no 24-week confirmed disability progression.

Results of Clinical Trials for CNM-Au8, A Potential ALS Treatment: James Berry, MD, MPH

The director of the Massachusetts General Hospital ALS Care Center talked about CNM-Au8 treatment across three populations, as well as the HEALEY ALS Platform Trial, at the 2023 AAN annual meeting. [WATCH TIME: 5 minutes]

Ocrelizumab Showed No Evidence of Disease Activity in Early-Remitting MS

Higher rates of no evidence of disease activity and no 24-week confirmed disability progression or relapses were observed in patients that continued with ocrelizumab.

Accuracy of DCTclock to Detect Cognitive Impairment: Ali Jannati, MD, PhD

The manager of Clinical Development-Research at Linus Health provided perspective on 2 analyses presented at the 2023 AAN Annual Meeting on the reliability of the DCTclock to detect cognitive impairment. [WATCH TIME: 4 minutes]

Low Dose Combination of Extended-Release Pramipexole and Rasagiline Shows Comparable Efficacy to Pramipexole Alone, With Greater Safety

No significant differences between P2B001 and Prami-ER were seen in total UPDRS responders, UPDRS Part II, and UPDRS Part III scores among those with Parkinson disease.

Development of Neuropathology Targeted Treatments in Alzheimer Disease: Madhav R. Thambisetty, MD, PhD

The senior investigator at the National Institute on Aging talked about targeting pathologies in neurodegenerative diseases at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

Higher Rates of Adverse Events, Discontinuations in Optimization Phase of Continuous Fosvelodopa/Foscarbidopa

Adverse events like dyskinesia, ON and OFF phenomenon, and falls, were all higher during the 4-week optimization phase than the 8-week maintenance phase.

ND0612 Significantly Improves ON Time in Parkinson Disease in Phase 3 BouNDless Trial

Compared with immediate-release levodopa/carbidopa, NeuroDerm’s 24-hour subcutaneous liquid infusion improved ON time without dyskinesia and with nontroublesome dyskinesia.

Atogepant Reports Positive Data for Episodic Migraine in Phase 3 Trial

Findings showed a significant reduction in mean monthly migraine days with atogepant 60 mg once daily for patients with episodic migraine compared with placebo across a 12-week period.

Ataluren Confirms Benefit in Nonsense Mutation DMD With Significant Results in Subgroup Analysis

In a subgroup of patients with 300 m to 400 m 6MWD scores in the phase 3 Study 041, ataluren (Translarna; PTC Therapeutics) showed particular improvements from baseline.

Preserving Cognitive Status in Pediatric Multiple Sclerosis: Kimberly O’Neill, MD

The pediatric neuroimmunology fellow at NYU Langone provided perspective on a study presented at AAN 2023 comparing cognitive trajectories of pediatric and adult multiple sclerosis. [WATCH TIME: 3 minutes]

Zavegepant Nasal Spray Proves to Be an Effective Acute Migraine Treatment

Zavegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, provided onset of pain relief as early as 15 minutes postdose and sustained benefits to 48 hours post dose.

Long-term Ofatumumab Treatment Shows Freedom From Disease Progression, Favors Earlier Initiation

The data, from the phase 3 ASCLEPIOS I and II trials and ALITHIOS open-label extension, suggest that most patients remained free from disease progression, with most progression being independent of relapse activity.

Ocrelizumab Induced Significant Depletion of B-cell Subsets in Relapsing-Remitting MS

An interim analysis showed no reduction in T-cell counts and their subsets as a consequence of B-cell depletion in the first year of treatment with ocrelizumab.

Phase 3 CHAMPION-NMOSD Trial With Ravulizumab Significantly Lowers Risk of Relapse

Updated results to the phase 3 CHAMPION-NMOSD trial of ravulizumab showed significantly lower HAI score worsening following treatment.

Targeting Neuroinflammation in Huntington Disease: Rajeev Kumar, MD

The medical director of the Rocky Mountain Movement Disorders Center talked about the motivations of the phase 2 study on ANX005 for Huntington disease at the 2023 AAN Annual Meeting. [WATCH TIME: 3 minutes]

Eculizumab Safe and Effective in Adolescents With Myasthenia Gravis, Small-Scale Study Suggests

FDA-approved for adults with generalized myasthenia gravis in 2016, eculizumab continued to show promising efficacy and safety responses in adolescents with the disease, regardless of on concomitant use of IVIG.

Identifying Gaps in Access to Accurate Information on Epilepsy Surgery: Daniel Correa, MD, MSc

The neurologist at Montefiore Medical Center, Albert Einstein College of Medicine, provided insight on the need to improve online resources that provide epilepsy surgery information to patients. [WATCH TIME: 4 minutes]

Associations Between Organ Health and Brain Function, Preserving Brain Health: Costantino Iadecola, MD

The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine spoke about preserving brain function through medical, sociopolitical, and educational efforts as part of his presentation at the 2023 AAN annual meeting. [WATCH TIME: 6 minutes]

Extended-Release Carbidopa/Levodopa Shows Tolerable Safety, Maintained Efficacy in Open-Label Extension

The majority of treatment-emergent adverse events from IPX203 were mild or moderate in nature, and occurred within the first 90 days of treatment.

New 12-Month Findings Highlight ALZ-801’s Clinical Effect on Alzheimer Biomarkers, Hippocampal Atrophy

Treatment with ALZ-801, an investigational agent in development for Alzheimer disease, resulted in more than 40% reduction in plasma p-tau181 at the end of the 12-month analysis.

Open-Label Analysis Highlights Long-Term Safety of BTK Inhibitor Tolebrutinib

There were no observed tolebrutinib dose effect for treatment-emergent adverse events in the double-blind portion, as well as no new safety signals seen for those who crossed over in the open-label extension.

Targeting Blood Vessels to Improve Treatment for Alzheimer Disease: Costantino Iadecola, MD

The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine talked about the importance of vascular health in preventing cognitive impairment as part of his presentation at the 2023 AAN annual meeting. [WATCH TIME: 6 minutes]